ArticleFEBS open bio2026
Aquaporin-3 and aquaporin-5 impact the development of pancreatic ductal adenocarcinoma spheroids.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related mortality, with poor survival due to late diagnosis and ineffective therapies. Aquaporin-3 (AQP3) and AQP5 are transmembrane proteins overexpressed in PDAC, promoting tumor progression and metastasis, representing promising therapeutic targets. Here, we investigated their involvement in PDAC spheroids' growth and morphology using two human PDAC cell lines, BxPC-3 and MiaPaca-2. Treatment with AQP3 inhibitors decreased spheroids' diameter, area, and viability and altered MiaPaca-2 spheroids' circularity, suggesting reduced growth. Similarly, silencing AQP3 or AQP5 in BxPC-3 spheroids decreased spheroids' size with a more pronounced viability reduction, indicating impaired growth and cell death. This study demonstrates, for the first time, the critical roles of AQP3 and AQP5 in PDAC spheroids' development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.